Key result
Chemotherapy agents, particularly anthracyclines and trastuzumab, cause cardiotoxicity in breast cancer patients, necessitating early cardiologist involvement and periodic cardiac monitoring.
Early involvement of a cardiologist and periodic cardiac monitoring are recommended to prevent and detect chemotherapy-induced cardiotoxicity in breast cancer patients.
Supports early cardiologist involvement during cardiotoxic breast cancer therapy; leaves open optimal protocols from prospective trials.
Chemotherapy-induced cardiotoxicity (CIC) is a well-documented side effect of breast cancer treatment. Nearly all chemotherapeutic agents can cause CIC with the highest occurrence found in anthracycline and trastuzumab use. Treatment- and patient-related risk factors contribute to the development of CIC making risk modification an important consideration during breast cancer treatment. Prevention and early detection of cardiotoxicity are key to minimizing permanent and devastating cardiac damage; therefore, early involvement of a cardiologist including periodic cardiac monitoring during and after chemotherapy exposure is recommended.
No takes yet. Share an insight, caveat, or question.
Ibraheem et al. (2016) conducted a review in Chemotherapy-induced cardiotoxicity in breast cancer. Chemotherapy (anthracyclines and trastuzumab) was evaluated on Chemotherapy-induced cardiotoxicity. Chemotherapy agents, particularly anthracyclines and trastuzumab, cause cardiotoxicity in breast cancer patients, necessitating early cardiologist involvement and periodic cardiac monitoring.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: